nail dystrophy
Conditions
Interventions
Superiority, parallel, randomized, double-blind, placebo-controlled clinical trial. After the initial assessment at baseline (T0), participants (n=80) will receive sufficient quantities of placebo sac
Sponsors
Faculdade de Medicina de Botucatu - Universidade Estadual Paulista
Faculdade de Medicina de Botucatu - Universidade Estadual Paulista
Eligibility
Sex/Gender
Female
Age
55 Years to 70 Years
Inclusion criteria
Inclusion criteria: Menopausal women; aged 55 to 70; living in the region of Botucatu; agreeing to participate in the study
Exclusion criteria
Exclusion criteria: Immunocompromised women or those using immunosuppressive drugs; diabetics; using anticoagulants or with coagulation disorders; using oral retinoids; patients with kidney disease; thyropathies and inflammatory and infectious diseases of the fingernails and current and previous clinical diagnosis or evidence of any medical condition that exposes the patient to increased risk; interferes with the safety or efficacy of the proposed treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main outcome of the study will be the difference in nail growth velocity of the second and fourth fingers of the dominant hand, measured 2 weeks after inclusion (T2) and at the end of follow-up (T14), as well as the difference in nail thickness measurement in the beginning and end of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes will be: nail stiffness of the second and fourth fingers of the dominant hand, dermal thickness of the posterior surface of the non-dominant arm, hair shaft thickness, GAIS and GSS assessment and frequency of adverse events | — |
Countries
Brazil
Contacts
Public ContactLuciana Alves
Faculdade de Medicina de Botucatu - Universidade Estadual Paulista
Outcome results
None listed